AXIOS September 24, 2021
Bob Herman

Generic drug companies have asked Pfizer, Moderna and Johnson & Johnson to license their COVID-19 vaccine technology to help increase global production, but so far the vaccine makers have given them the cold shoulder.

Why it matters: Other companies are saying they have extra capacity to make more vaccines. Not using that extra capacity could prolong the pandemic throughout the world.

What they’re saying: “Right now our biggest problem is that we cannot produce enough vaccine to meet the high demand,” Moderna CEO St├ęphane Bancel told a Swiss newspaper this week.

Behind the scenes: Several generics manufacturers have reached out to Pfizer, Moderna and Johnson & Johnson, and “none of their offers have been met positively,” said one industry source,...

Today's Sponsors

ZeOmega
Holon
Transcarent

Today's Sponsors

Crossover Health
Qure4u

Today's Sponsor

Institute for Healthcare Improvement

 
Topics: Biotechnology, Govt Agencies, Healthcare System, Pharma / Biotech, Public Health / COVID
Drug overdoses surged during the pandemic. Providers are thinking outside the box to combat the opioid crisis
Use of digital tools for clinical trials triples during pandemic; survey
Anti-Covid Drugs Are Coming, But At What Cost?
The post-pandemic evolution of pharma-doctor digital interactions
New COVID-19 drug therapies are on the horizon, but will they matter?